Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53 - Induced apoptosis

Neuro-Oncology

Volumn 10, Issue 3, 2008, Pages 275-291

  Nakamizo, Akira ^b,c   Amano, Toshiyuko ^b,c   Zhang, Wei ^a   Zhang, Xin Qiao ^a   Ramdas, Latha ^a   Liu, Ta Jen ^a   Bekele, Nebiyou ^a   Shono, Tadahisa ^c   Sasaki, Tomio ^c   Benedict, William F ^a   Sawaya, Raymond ^b   Lang, Frederick F ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle arrest; Glioma; P53; Phosphorylation

Indexed keywords

PROTEIN P53; SERINE; THREONINE;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE PHASE; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE;

ADENOVIRIDAE; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOPRECIPITATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; SERINE; THREONINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60849084865     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-015     Document Type: Article

References (55)

1. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998;12:2973-2983.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
3. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998; 95:5-8.
4. Vousden KH. p53: death star. Cell. 2000;103:691-694.
5. Kastan MB. Wild-type p53: tumors can't stand it. Cell. 2007;128:837-840.
6. Frankel RH, Newcomb EW, Koslow M, Bayona W. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res. 1992;52:1427-1433.
7. Kyritsis AP, Amos CJ, Zhu D, et al. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995;1:1617-1622.
8. von Deimling A, Seizinger BR, Louis DN, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 1992;52:2987-2990.
9. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127:1323-1334.
10. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661-665.
11. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-660.
12. Lang FF, Yung WKA, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery. 1999;45:1093.
13. Lang FF, Bruner JM, Fuller GN, et al. Phase I trials of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508-2518.
14. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 2002; 62:6165-6171.
15. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95:652-660.
16. Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther. 2006;17:291-302.
17. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282-288.
18. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
19. Gomez-Manzano C, Kyritsis AP, Roth JA, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996; 56:694-699.
20. Gomez-Manzano C, Kyritsis AP, Fueyo J, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst. 1997;89:1036-1044.
21. Cerrato JA, Liu TJ, Yung WK. Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro-Oncology. 2001;3:113-122.
22. Lang FF, Yung WK, Raju U, Libunao F, Terry NH, Tofilon PJ. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg. 1998;89:125-132.
23. Shono T, Parikh D, Lang FF, Tofilon PJ, Liu TJ, Schaefer TS. Apop-tosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 2002;62:1069-1076.
24. Colletier PJ, Pollack A, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys. 2000;48:1507-1512.
25. Kawabe S, Munshi A, Wilson DR, Roth JA, Zumstein LA, Meyn RE. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int J Radiat Biol. 2001 ;77:185-194.
26. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999;19:1751-1758.
27. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem. 2004;279:53015-53022.
28. Unger T, Yee CL, Moallem E, et al. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene. 1999;18:3205-3212.
29. Chao C, Herr D, Chun J, Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 2006;25:2615-2622.
30. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003;15:164-171.
31. Jimenez GS, Khan SH, Stommel JM, Wahl GM. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 1999;18:7656-7665.
32. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apopto-sis. Nat Cell Biol. 2002;4:11-19.
33. Saito S, Goodarzi AA, Higashimoto Y, et al. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem. 2002;277:12491-12494.
34. Jabbur JR, Huang P, Zhang W. Enhancement of the antiproliferative function of p53 by phosphorylation at serine 20: an inference from site-directed mutagenesis studies. Int J Mol Med. 2001;7:163-168.
35. Jabbur JR, Tabor AD, Lozano G, et al. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 2002;21:7100-7113.
36. Jabbur JR, Zhang W. p53 antiproliferative function is enhanced by aspartate substitution at Threonine 18 and Serine 20. Cancer Biol Ther. 2002;1:277-283.
37. Bett AJ, Graham FL, Prevec L, Haddara W. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. 1994; 91:8802-8806.
38. Hu L, Fuller GN, Wang H, et al. Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics. 2002;3:16.
39. Wang H, Fuller GN, Huang H, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion- enhancing genes. Cancer Res. 2003; 63:4315-4321.
40. Baggerly KA, Stivers DN, Coombes KR, Hess KR, Abruzzo LV, Zhang W. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol. 2001;8:639-659.
41. Weinmann AS, Farnham PJ. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods. 2002;26:37-47.
42. Oda K, Tanikawa C, Arakawa H, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphory-lated p53. Cell. 2000;102:849-862.
43. Wang XW, Fornace AJ, Harris CC, et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A. 1999;96:3706-3711.
44. Zhan Q, Fornace AJ, Harris CC, et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein GADD45. Oncogene. 1999;18:2892-2900.
45. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345-357.
46. MacPherson D, Kim J, Kim T, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004;23:3689-3699.
47. Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem. 2004;279:7598-7605.
48. Mayo LD, Seo YR, Jackson MW, et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem. 2005;280:25953-25959.
49. Wu Z, Earle J, Saito S, Anderson CW, Appella E, Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol. 2002;22:2441-2449.
50. Chao C, Hergenhahn M, Kaeser MD, et al. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem. 2003;278:41028-41033.
51. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy- induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 2007;26:3473-3481.
52. Unger T, Moallem E, Lozano G, et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by MDM2. EMBO J. 1999;18:1805-1814.
53. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A. 1999;96:13777-13782.
54. Shieh SY, Prives C, Ikeda M, Taya Y. DNA damaged-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
55. Shieh SY, Prives C, Taya Y. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramer-ization. EMBO J. 1999;18:1815-1823.